MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Neuroprotective agents"

  • 2024 International Congress

    Neurotinib, a Brain Penetrant c-Abl Inhibitor, Prevents Activation and Phosphorylation of c-Abl Kinase and Alpha-Synuclein

    N. Tayebi, B. Berhe, B. Aleksandra, J. Lichtenberg, A. D'Souza, M. Henderson, T. Chen, A. Alvarez, S. Zanlungo, M. Cookson, J. Marugan, E. Sidransky (Bethesda, USA)

    Objective: Objective: To investigate Neurotinib, a newly developed allosteric c-Abl inhibitor, as a neuroprotective agent in a murine GBA1-associated Parkinson's disease (PD) model. Background: The…
  • 2024 International Congress

    Validating the clinical stage NLRP3 inflammasome inhibitor nibrozetone as a disease-modifying therapeutic for Parkinson’s disease

    R. Gordon, K. Bhatt, N. Jayabalan, N. Birch, A. Lehn, B. Oronsky, S. Caroen, T. Reid (Brisbane, Australia)

    Objective: We recently confirmed that nibrozetone (RRx-001), a Phase 3 small molecule chemoprotective agent, is a direct NLRP3 inhibitor that is CNS permeable. Nibrozetone displays…
  • 2024 International Congress

    Deciphering the Role of Auranofin-Loaded Nanoparticles Against Rotenone Model of Parkinson’s Disease: Via GSK-3β/ Nrf2/HO-1 Signaling Pathways

    D. Soni, P. Kumar (Bathinda, India)

    Objective: To investigate the neuroprotective effect of AUF-loaded nanoparticles in animal models of Parkinson's disease by modulating GSK-3β/ Nrf2/HO-1 Signaling Pathways. Background: Parkinson's disease (PD) is…
  • 2024 International Congress

    Understanding the neuroprotective mechanism of ilex Paraguariensis (Yerba mate) in a Drosophila melanogaster alpha-synuclein model of Parkinson’s disease

    A. Tschopp, P. Ballestero, G. Decurgez, H. Hauche, T. Eidelman, M. Bordone, N. Muraro, J. Ferrario (CABA, Argentina)

    Objective: To investigate behavioral and cellular changes in the brain of a Drosophila melanogaster model of Parkinson’s Disease (PD) exposed to yerba mate [YM] extract.…
  • 2024 International Congress

    ilex Paraguariensis (Yerba mate) modulates the AMPK pathway and downstream key metabolic mechanism that may explain its neuroprotective role.

    J. Ferrario, H. Hauche, L. Tschopp, T. Eidelman, M. Bordone (Buenos Aires, Argentina)

    Objective: To investigate the molecular pathways regulated by yerba mate [YM] extract and its main active compounds in a neuronal cell line as a cue…
  • 2024 International Congress

    Exercise-induced angiogenesis and midbrain neuroprotection in a mouse model of experimental PD

    T. Rodriguez, R. Smeyne, M. Smeyne (Philadelphia, USA)

    Objective: The goal of this study is to characterize microvascular changes in the SNpc in response to a neuroprotective bout of exercise. Background: Parkinson’s disease…
  • 2024 International Congress

    Time-Restricted Eating in Huntington’s Disease: Review of the Literature and a Proposed Clinical Trial

    R. Wells, L. Neilson, A. Mchill, A. Hiller (Portland, USA)

    Objective: Review recent literature on time-restricted eating (TRE) in Huntington’s disease (HD) and outline our protocol for an upcoming clinical trial designed to assess the…
  • 2024 International Congress

    Exploring the Neuroprotective Effects of Diurnal Light Exposure in Early-Stage Parkinson’s Disease: A Longitudinal, Multi-Sensory Intervention Study

    S. Putri, R. Fajar, E. Syafruddin (Gresik, Indonesia)

    Objective: This study aims to explore the neuroprotective effects of controlled diurnal light exposure on neurodegeneration rates in early-stage PD patients, positing that light therapy…
  • 2024 International Congress

    Selecting an Imaging Biomarker for a Multi-Arm Multi-Stage Trial of Disease-Modifying Treatments for Parkinson’s: The EJS ACT-PD Experience

    C. Gonzalez-Robles, S. Al-Bachari, M. Bartlett, R. Petty, S. Collins, R. Ellis-Doyle, G. Mills, P. Piccini, K. Pushparatnam, C. Siu, Z. Walker, M-L. Zeissler, C. Carroll, T. Foltynie, R. Weil, A. Schrag, C. Lambert (London, United Kingdom)

    Objective: To report on the selection of an imaging biomarker for a sub-study in a multi-arm, multi-stage (MAMS) platform trial for disease-modifying therapies (DMTs) in…
  • 2024 International Congress

    Therapeutic restoration of Faecalibacterium prausnitzii in Parkinson’s disease using targeted fructoligosaccharides: a double-blind, placebo-controlled, cross-over trial

    J. O'Sullivan, N. Jayabalan, N. Birch, D. Mondhe, A. Lehn, R. Gordon, R. Adan (Brisbane, Australia)

    Objective: In this study, we evaluated the effect of targeted fructoligosaccharide (FOS) therapy to restore the beneficial butyrate producer Faecalibacterium prausnitzii, one the most highly reduced…
  • 1
  • 2
  • 3
  • …
  • 13
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • To be or not to bupropion: a drug-induced parkinsonism?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • An atypical and interesting feature of Parkinson´s disease
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley